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Abstract: Breast magnetic resonance imaging (MRI) is considered the technique with the 
highest sensitivity for breast cancer detection. Gadobenate dimeglumine is a gadolinium-based 
contrast agent (GBCA) that is specifically approved in Europe for breast MRI and which has the 
highest r1 relaxivity among all GBCAs for this indication. In order to improve the diagnostic 
performance of breast MRI, several intra-individual crossover studies have evaluated gadobenate 
dimeglumine as a possible GBCA for this application. This review focuses on the role and 
advantages of gadobenate dimeglumine as a contrast agent for breast MRI by describing the 
unique properties of this agent and by summarizing published studies.
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Introduction
Breast cancer is the most common cancer among women, accounting for over one fifth 
of the estimated annual 4.7 million cancer diagnoses in females. It is the main cause 
of death from cancer in women.1,2 Conventional X-ray mammography and ultrasound 
are the most widely used techniques for breast imaging but have comparatively low 
sensitivity and specificity for dense breast evaluation or in patients with breast implants, 
post-surgical scars or deformity.2–7 Of the techniques available, magnetic resonance 
imaging (MRI) has consistently demonstrated superior sensitivity to conventional 
imaging techniques for breast cancer detection.8,9 In this regard, a recent meta-analysis 
of 44 studies revealed an overall sensitivity of 0.90 for MRI in the evaluation of breast 
cancer.10 Although specificity was somewhat lower at 0.72, this reflected the inclusion 
of several studies published during the early days of breast MRI when specificity was 
still an issue.
In recent years the role of breast MRI has increased dramatically. Among the 
many applications for breast MRI are detection of primary and recurrent breast 
cancer, screening for high-risk women, evaluation of the response to neoadjuvant 
chemotherapy, preoperative staging, and assessment of breast implants.11–17
MRI is advantageous for breast imaging because of high soft-tissue contrast 
and the possibility for multiplanar sectioning which permits full three-dimensional 
representation of one or both breasts. With recent technological improvements in 
imaging technique, as well as standardization of image acquisition and interpretation, 
breast MRI enhanced with gadolinium-based contrast agents (GBCAs) is now widely 
accepted as an integral part of clinical practice at most centers.18






Gadolinium is a rare earth metal which belongs to the lan-
thanide family of elements; it is a highly paramagnetic element 
having seven unpaired electrons which make it highly suitable 
for MRI.19 As free gadolinium is highly toxic, all GBCAs 
consist of gadolinium bound to an organic chelating molecule. 
The GBCAs available for breast MRI have an extracellular 
distribution with a half-life of elimination of approximately 
1.5–2.0 hours in patients with normal renal function.19,20 The 
approved contrast agent dose is 0.1 mmol/kg of body weight 
which is usually injected at a rate of 2–3 mL/s.19,20
GBCAs shorten the T1, T2, and T2* relaxation time con-
stants of adjacent water protons in tissues producing signal 
enhancement on T1-weighted MR images and signal loss on 
T2- and T2*-weighted MR images.19 The extent to which a 
GBCA shortens the relaxation times depends on the relaxivity 
of the agent. GBCAs have different structures and physico-
chemical properties but most have similar r1 relaxivity values 
of 3.9–4.6 L/mmols-1 at 1.5 T.21 Of the GBCAs available 
for breast imaging gadobenate dimeglumine (MultiHance®; 
Bracco imaging, Milan, Italy) has a markedly higher r1 
relaxivity in vivo of 6.2 L/mmols-1 at 1.5 T.
Several studies have demonstrated an association between 
the use of contrast agents with higher r1 relaxivity and stronger 
contrast enhancement in comparison to  contrast agents with 
lower r1 relaxivity. For most clinical applications, the stronger 
enhancement has been shown to be associated with a clinically 
relevant gain in diagnostic performance.22–26
GBCAs and breast MRI
The first GBCA utilized for breast MRI was gadopentetate 
dimeglumine.27 Since then several other GBCAs have been 
evaluated. Renz et al evaluated 45 patients with gadoteric 
acid and gadobutrol and while some differences were noted 
in terms of the dynamic and morphologic characterization 
of breast lesions, both GBCAs were considered reliable for 
breast MRI.28 More recently, Fallenberg et al performed an 
intra-individual comparison of the same two GBCAs and 
observed a stronger relative signal intensity enhancement 
with gadobutrol. However, no significant differences were 
noted in terms of the characterization of breast lesions.29
Gadobenate dimeglumine 
(MultiHance) in breast MRI
Gadobenate dimeglumine differs from other GBCAs approved 
for breast MRI in that it possesses a  benzyloxymethyl 
 substituent on the chelate structure. This substituent causes 
the gadobenate molecule to interact weakly, transiently, 
and non-covalently with human serum albumin, a principal 
 consequence of which is a slowing of the tumbling rate of the 
gadolinium complex and thus greater relaxivity (and hence 
shorter T1, T2, and T2* relaxation times) than GBCAs that 
do not interact with serum albumin.30
Since neoangiogenesis in breast cancer is associated with 
increased vascularity and permeability, breast  malignancies 
typically show higher contrast enhancement than normal 
breast parenchyma following GBCA  administration. The 
greater r1 relaxivity of gadobenate dimeglumine deriving 
from interaction with serum albumin is therefore potentially 
highly beneficial for the improved detection of malignant 
breast lesions with abnormal vascular permeability in which 
the concentration of serum albumin is likely to be increased.
Numerous advantages to the use of gadobenate dimeglu-
mine for breast MRI have been described in the literature 
and a great deal of data are available on the diagnostic 
 performance achievable with this GBCA (Table 1).22–26
An early study to establish the optimal dose of  gadobenate 
dimeglumine to use for breast MRI established that 
0.1 mmol/kg of bodyweight is superior to doses of 0.05 and 
0.2 mmol/kg of bodyweight in terms of lesion  detection in 
women with known or suspected breast  cancer.22  Furthermore, 
0.1 mmol/kg gadobenate dimeglumine was also shown to be 
significantly superior to an equivalent dose of gadopentetate 
dimeglumine, not only in terms of malignant lesion detection 
but also for quantitative contrast enhancement and sensitiv-
ity for lesion characterization, meaning that detected lesions 
were easier to see and  classify.  Importantly, fewer false 
positive determinations were made with 0.1 mmol/kg gado-
benate dimeglumine than with 0.1 mmol/kg gadopentetate 
 dimeglumine. Unfortunately, a limitation of dose-finding stud-
ies of this type is that they necessarily have an inter-individual 
design in which patients receive just one contrast-enhanced 
examination and results are compared between groups. Such 
studies are subject to wide between-group variability in terms 
of patient population, breast density, size and type of lesions 
etc, making it difficult to accurately adjudicate the contrast 
efficacy of one agent against another.
A more accurate comparison of contrast agent efficacy 
is achieved with intra-individual crossover studies in which 
patients receive both contrast agents in two otherwise 
identical MRI examinations separated by just a few days. 
A first study of this type with gadobenate dimeglumine in 
breast MRI was performed by Pediconi et al23 in 2005 in 26 
women with suspected breast cancer based on findings from 
conventional imaging. Significantly superior detection of 
breast lesions and more accurate identification of malignant 
lesions were achieved with 0.1 mmol/kg gadobenate dime-
glumine than with 0.1 mmol/kg gadopentetate dimeglumine. 
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Specifically, MRI with gadobenate dimeglumine depicted 
significantly (P=0.003) more lesions (45 of 46) than did MRI 
with gadopentetate dimeglumine (36 of 46), and detected 
lesions were significantly (P,0.001) more conspicuous with 
gadobenate dimeglumine. Likewise, confidence for lesion 
characterization was significantly (P=0.031) greater with 
gadobenate dimeglumine. Comparison of the contrast agents 
for their ability to help identify malignant lesions revealed 
significant (P=0.02) superiority for gadobenate dimeglumine: 
sensitivity, specificity, positive predictive value, negative 
predictive value, and overall accuracy for malignant lesion 
identification were, respectively, 94.7%, 100%, 100%, 80.0%, 
and 95.6% with gadobenate dimeglumine and 76.3%, 100%, 
100%, 47.1%, and 80.4% with gadopentetate dimeglumine. 
 Quantitative evaluation of signal intensity-time curves 
revealed significantly (P,0.001) greater lesion enhancement 
with gadobenate dimeglumine.
A similar study in 2008 in a larger number of patients 
revealed similar findings.24 In that study 47 women with 78 
histologically proven breast cancers underwent breast MRI 
examinations with 0.1 mmol/kg gadobenate dimeglumine and 
0.1 mmol/kg gadopentetate dimeglumine. Again, gadobenate 
dimeglumine provided significantly better performance for 
the detection of breast lesions (75/78 lesions detected in total 
with gadobenate dimeglumine compared with 62/78 lesions 
detected with gadopentetate dimeglumine; 49/50 malignant 
lesions detected with gadobenate dimeglumine compared with 
38/50 malignant lesions detected with gadopentetate dimeglu-
mine) and provided significantly better diagnostic performance 
(sensitivity 98.0% vs 76.0%; specificity 71.4% vs 57.1%; accu-
racy 88.5% vs 69.2%; positive predictive value 86.0% vs 76.0%; 
and negative predictive value 95.2% vs 57.1%).
Based on these single-center studies a much larger clinical 
trial was performed in order to obtain marketing  authorization 
for gadobenate dimeglumine for breast MRI in Europe. 
This trial (the DETECT trial, a multicenter, double-blind, 
 randomized, intra-individual, crossover comparison between 
gadobenate dimeglumine and gadopentetate dimeglumine for 
breast MRI)25 prospectively randomized 162 patients at 17 sites 
in Europe and People’s Republic of China between 2007 and 
2009 to undergo two breast MRI exams, one with gadobenate 
dimeglumine and the other with  gadopentetate dimeglumine, 
each at a dose of 0.1 mmol/kg of body weight.
Overall 157/162 women received gadobenate dimeglumine 
and 155/162 women received gadopentetate dimeglumine. 
The three readers of the study reported signif icantly 
 superior  cancer detection with gadobenate dimeglumine. 
This  superiority was noted for all malignant lesions includ-
ing non-invasive carcinomas (gadobenate dimeglumine 
detected 17 non-invasive  cancers while gadopentetate 
Table 1 Breast MRi: cross-over studies between gadobenate dimeglumine and other GBCAs
Reference Indication Design of study Comparators/number of patients Results





Superiority of gadobenate dimeglumine not only 
in terms of malignant lesion detection but also  
in terms of sensitivity for lesion characterization
Pediconi et al23 Breast cancer intra-individual Gadobenate dimeglumine 0.1 mmol/kg 
Gadopentetate dimeglumine 0.1 mmol/kg 
26 patients
Gadobenate dimeglumine significantly superior  
to gadopentetate dimeglumine – greater 
sensitivity and accuracy in the detection of  
breast cancer nodules
Pediconi et al24 Breast cancer intra-individual Gadobenate dimeglumine 0.1 mmol/kg 
Gadopentetate dimeglumine 0.1 mmol/kg 
double-blind, randomized, crossover, 
47 patients
Gadobenate dimeglumine significantly superior  
to gadopentetate dimeglumine – greater accuracy 
in the detection and characterization of breast 
cancer nodules
Martincich et al25 Breast cancer intra-individual Gadobenate dimeglumine 0.1 mmol/kg 
Gadopentetate dimeglumine 0.1 mmol/kg  
double-blind, randomized, crossover, 
157 patients
MRi with gadobenate dimeglumine had 
significantly better diagnostic performance 
(greater sensitivity, specificity, and predictive 
values) than MRi with gadopentetate dimeglumine
Gilbert et al26 Breast cancer intra-individual Gadobenate dimeglumine 0.1 mmol/kg 
Gadopentetate dimeglumine 0.1 mmol/kg 
double-blind, randomized, crossover, 
153 patients 
Significantly better diagnostic performance on 
MRi with gadobenate dimeglumine than on MRi 
with gadopentetate dimeglumine and significantly 
better breast cancer detection compared with 
conventional imaging techniques 
Pediconi et al33 Breast cancer intra-individual Gadobenate dimeglumine  
(0.5 M) 0.1 mmol/kg 
Gadobutrol (1 M) 0.1 mmol/kg
Non-inferiority of gadobutrol in comparison 
with gadobenate dimeglumine for breast lesion 
detection
Abbreviations: MRi, magnetic resonance imaging; GBCAs, gadolinium-based contrast agents.





dimeglumine  identified only eleven of the 17 cancers 
detected by gadobenate  dimeglumine). Readers preferred 
gadobenate  dimeglumine over gadopentetate dimeglumine 
for  determinations of lesion conspicuity and lesion border 
delineation. Moreover the rate of cancer misdiagnosis was 
lower for gadobenate  dimeglumine (2.6%, 4.0%, 3.5% for 
gadobenate dimeglumine vs 4.9%, 6.6%, and 11.9% for 
gadopentetate dimeglumine; readers 1, 2, and 3, respectively). 
Further analysis of data from this study revealed significant 
superiority for gadobenate dimeglumine not only for lesion 
detection across different malignant lesion types, but also 
across different categories of breast parenchyma density.26 
Moreover, highly significant superiority for malignant lesion 
detection was noted compared to conventional mammogra-
phy and ultrasound (Figures 1 to 3).26
The results of all these intra-individual crossover  studies23–26 
can be ascribed to the greater r1 relaxivity of gadobenate 
dimeglumine compared to gadopentetate dimeglumine 
(6.2 L/mmols-1 vs 4.2 L/mmols-1 at 1.5 T).21 Since r1 relaxiv-
ity is the single most important para meter defining contrast 
efficacy in terms of signal intensity enhancement, similar 
superiority for gadobenate  dimeglumine can be anticipated for 
 intra-individual  comparisons of this agent with other GBCAs 
that have r1 relaxivity values similar to that of gadopentetate 
dimeglumine.
That breast MRI is demonstrably superior to conventional 
imaging techniques was further shown by Pediconi et al in 
2007 in a study in 118 patients with unilateral breast cancer 
or high-risk lesions and negative findings in the contralateral 
breast.31 Breast MRI with 0.1 mmol/kg gadobenate dimeglu-
mine at 1.5 T resulted in the detection of contralateral lesions 
in 28 (24%) patients, predominantly in women with dense 
breast parenchyma. The sensitivity, specificity, accuracy, and 
positive and negative predictive values of gadobenate dime-
glumine-enhanced breast MRI for depiction of malignant or 
high-risk contralateral lesions were 100%, 94%, 95%, 79%, 
and 100%, respectively. In a similar study Viehweg et al32 
obtained sensitivity, specificity, and accuracy values of 91%, 
Figure 1 48-year-old woman with Bi-RADS 6 lesions in the right breast detected on 
XR mammography and ultrasound (triple negative, iDC). 
Notes: woman underwent breast MRi with gadobenate dimeglumine (MultiHance®;) 
for local staging. MRi detected more nodules in the right breast than conventional 
imaging and allowed a better evaluation of skin thickness. it was considered 
multicentric disease and neoadjuvant chemotheraphy was planned. Breast MRi 
also revealed an enhancing lesion in the left breast, not detected on conventional 
imaging; second look ultrasound was performed and histological examination proved 
a DCiS: (A–B) iDeAL water only T2w sequence, axial plane. The grey arrow shows 
skin thickness while black arrows indicate a round, hyperintense nodule in the right 
breast. viBRANT T1w precontrast sequence, axial plane, 3T magnet. (C) viBRANT 
T1w dynamic sequence, axial plane, 3T magnet. The lesion between inferior quadrants 
of the right breast has a central area of necrosis (black arrow) and multiple nodules 
are detectable in the ipsilateral breast (grey arrow). in the left breast there is an 
enhancing nodule (arrowhead).
Abbreviations: MRi, magnetic resonance imagining; Bi-RADS, Breast imaging-
reporting and data system; iDC, invasive ductal carcinoma; XR, X-ray; DCiS, ductal 
carcinoma in situ.
Figure 2 38-year-old woman with nipple retraction.
Notes: Ultrasound did not detect any lesions. Breast MRi with gadobenate 
dimeglumine (MultiHance) confirmed nipple retraction and detected non mass-
like enhancement with nipple involvement. (A) T1w sequence, axial plane. Nipple 
retraction is due to retroareolar non-mass enhancement (white arrow). iS/T curve 
type ii–iii. The patient underwent surgery and it was proven to be iDC. (B) T2w 
water only sequence, nipple retraction is recognizable (white arrow).
Abbreviations: MRi, magnetic resonance imagining; iDC, invasive ductal carcinoma.
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Unique features of gadobenate 
dimeglumine for breast MRI
In the DETECT trial25 no statistically significant  differences 
were observed between gadobenate dimeglumine and 
 gadopentetate dimeglumine in terms of the appearance 
of the signal intensity-time curves for individual lesions 
although the  magnitude of  contrast enhancement was sig-
nificantly higher with gadobenate dimeglumine.25 A potential 
benefit of this higher contrast enhancement is improved 
diagnostic  performance relative to breast MRI with lower 
 relaxivity GBCAs. In  looking to investigate the potential for 
improved  diagnostic  performance  Sardanelli et al35 evalu-
ated 34 patients with 36 breast lesions and ascribed a score 
based on shape (round/oval/lobular =0;  linear/dendritic/stel-
late =1),  margins (defined =0;  undefined =1), enhancement 
pattern ( homogeneous =0;  inhomogeneous =1; rim =2), 
 kinetics ( continuous =0; plateau =1; washout =2), and initial 
 enhancement. For the assessment of initial enhancement 
a standard threshold score (ie, ,50% =0; 50%–100% =1; 
.100% =2) was compared with an adjusted threshold score 
in which ,100% =0; 100%–240% =1; .240% =2. Overall, 
33 lesions (26 malignant and seven benign) had an initial 
enhancement higher than 100%, of which 17 had initial 
enhancement greater than 240%. Application of adjusted 
thresholds led to improved specificity (75% with adjusted 
thresholds vs 13% with standard thresholds) without affecting 
sensitivity (96%) for malignant lesion detection. Values for 
accuracy, positive predictive value, and negative predictive 
value were also better with adjusted thresholds (92%, 93% 
and 86%, respectively, with adjusted thresholds vs 78%, 79%, 
and 50% respectively, with standard thresholds). A subsequent 
study in 68 patients with 73 lesions revealed similar results:36 
the initial enhancement for benign lesions was 141%±65% 
(mean ± standard deviation) compared with 210%±80% 
(P=0.001) for malignant lesions resulting in improved 
specificity, accuracy, positive predictive value, and negative 
predictive value without affecting the sensitivity (100%) for 
malignant lesion detection.
A second benefit of the higher relaxivity of gadobenate 
dimeglumine for breast MRI is the possibility for improved 
malignant lesion detection based on an association between 
cancer and increased breast vascularity.37–39 Gadobenate 
dimeglumine is ideally suited to vascular imaging because of 
its greater r1 relaxivity derived from interaction with human 
serum albumin. Since neoangiogenesis and increased breast 
vascularity is associated with breast cancer, improved depic-
tion of ipsilateral increased vascularity is highly indicative of 
Figure 3 Breast MRi of a 59-year-old woman revealed a greater extension of the 
lesion on the right breast than XR mammography and ultrasound. At pathology both 
lesions were proved to be invasive ductal carcinoma.
Notes: T1w sequence, axial plane. Breast MRi with gadobenate dimeglumine 
(MultiHance) allowed detection of two lesions in both breasts. Non-mass 
enhancement in the right breast was previously underestimated at XR mammography 
and ultrasound. (A) T1w sequence after gadobenate dimeglumine (MultiHance). 
Non-mass enhancement (grey arrow); type iii curve (B) T1w sequence after 
contrast agent. Mass lesion (grey arrow). Type iii curve.
Abbreviations: MRi, magnetic resonance imagining; XR, X-ray.
90%, and 90%, respectively, for the detection of contralateral 
malignant lesions but used a double (0.2 mmol/kg) dose of 
gadopentetate dimeglumine.
Although these previous studies have all demonstrated 
diagnostic superiority for gadobenate dimeglumine, the 
choice of alternative contrast agents is an important issue in 
daily practice. For this reason Pediconi et al performed an 
intra-individual randomized comparison of gadobutrol versus 
gadobenate dimeglumine.33
The study included 72 patients, each of whom underwent 
two preoperative breast MRI examinations with gadobenate 
dimeglumine and gadobutrol. No significant differences 
were observed between the two contrast agents in terms 
of lesion detection, Breast Imaging-Reporting and Data 
System assessment or lesion enhancement and morphology 
and the authors concluded that gadobutrol is non-inferior to 
gadobenate dimeglumine for breast cancer staging.33 How-
ever, unlike the comparisons of gadobenate dimeglumine 
and gadopentetate dimeglumine22–26 this study was open to 
criticism in terms of the patient inclusion criteria and the 
manner in which the study end-points were selected and 
analyzed.34





malignancy (Figure 4). A study by Sardanelli et al revealed 
better evaluation of breast vessels and improved detection 
of one-sided increased vascularity with 0.1 mmol/kg gado-
benate dimeglumine than with 0.1 mmol/kg gadopentetate 
dimeglumine.39 Specifically, 95 women with known or 
suspected breast cancer underwent breast MRI, receiving 
either gadobenate dimeglumine at a dose of 0.05, 0.1 or 0.2 
mmol/kg bodyweight or gadopentetate dimeglumine at a dose 
of 0.1 mmol/kg bodyweight. Assessment was then made of 
maximum intensity projection images since these images, 
obtained by post-processing subtracted (post-contrast – 
pre-contrast) breast images, reveal not only the presence of 
enhanced lesions but also the angiographic vascular map of 
vessels within the breast. A score ranging from 0, indicating 
absent or very low breast vascularity, to 3, indicating high 
breast vascularity, was assigned to the maximum intensity 
projection images on the basis of the number of vessels 
seen and the length and conspicuity of the vessels. Breast 
increased vascularity was assumed when the difference 
in the number of vessels between the two breasts was two 
or more. Overall, 67 patients demonstrated asymmetric 
breast vascularity due to the presence of one-sided increased 
vascularity.  Statistically significant differences in vascular 
map scores were observed between the three gadobenate 
dimeglumine dose groups and the gadopentetate dimeglu-
mine dose group. Notably, significant differences between the 
gadobenate dimeglumine groups were not observed; a dose 
of just 0.05 mmol/kg bodyweight was shown to produce high 
quality vascular maps of the breast and that the angiographic 
effect at this and higher doses is significantly greater than the 
effect following the administration of a standard 0.1 mmol/kg 
dose of gadopentetate dimeglumine. This study confirmed the 
association between vascular map asymmetry and ipsilateral 
invasive breast cancer with sensitivity and specificity values 
of 88% and 82%, respectively, for ipsilateral malignancy.39
Possible adverse effects of 
gadobenate dimeglumine
Although GBCAs have long been considered extremely 
safe, their safety has been of growing concern following 
the advent of nephrogenic systemic fibrosis (NSF).40 NSF 
is a rare  disease which occurs in patients with severe renal 
impairment, particularly in the presence of a proinflammatory 
process. Available data do not reveal an increased risk of NSF 
for gadobenate dimeglumine (no unconfounded cases of NSF 
have been reported with this agent) and it is considered safer 
than other GBCAs, such as gadodiamide and gadopentetate 
dimeglumine, in patients with renal impairment.41–43 Numer-
ous studies reveal a robust safety profile for this agent.
Conclusion
A number of studies have shown that gadobenate dimeglu-
mine is superior to other GBCAs for breast MRI in allowing 
improved diagnostic performance.
The use of gadobenate dimeglumine for breast MRI is 
 preferable to other GBCAs. Its higher relaxivity helps improve 
the detection and characterization of malignant breast lesions 
at an equivalent dose to that of other GBCAs such as gadopen-
tetate dimeglumine. Based on available data the  identification 
of breast lesions is improved with the use of gadobenate 
 dimeglumine and the rate of cancer misdiagnosis is lower.
Figure 4 A 53-year-old woman with multiple lesions of the right breast, as seen 
on a breast ultrasound, proved to be invasive ductal carcinoma at pathology. 
She underwent a breast MRi to determine the extent of the disease and the 
multicentricity.
Notes: (A) T2w sequence, axial plane, 1.5T magnet. Asymmetry between breasts 
and skin thickness (grey arrow) of the right breast are recognizable. (B) T1w dynamic 
sequence. After gadobenate dimeglumine (Multihance) administration it is possible 
to detect multiple enhancing lesions (black arrows) in the right breast. Moreover 
skin and nipple-areola complex (grey arrow) involvement are well appreciable. iS/T 
curve type iii. (C) Maximum intensity projection (MiP) images in the axial plane. The 
right breast shows increased vascularity (grey arrows).
Abbreviations: MRi, magnetic resonance imagining.
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